Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07000123 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
A Phase 3 study of Cardiovascular Disease, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 3,046
- Enrollment target
- 20
- Study locations
NCT07000123: Active Phase 3 study of Cardiovascular Disease, sponsored by AstraZeneca.
NCT07000123 is a Phase 3 study of Cardiovascular Disease that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 3,046 participants, above the 2,675-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07000123, a Phase 3 study of Cardiovascular Disease, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 3,046 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.
Primary Outcome
To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 12 weeks
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD0780
Study Locations (20)
California
- Research Site - Garden Grove
- Research Site - Gardena
- Research Site - Lancaster
- Research Site - Lincoln
- Research Site - San Diego
- Research Site - San Diego
- Research Site - Torrance
- Research Site - West Hills
Florida
- Research Site - Boca Raton
- Research Site - Hallandale
- Research Site - Hialeah
- Research Site - Inverness
- Research Site - Jacksonville
Alabama
- Research Site - Huntsville
- Research Site - Irondale
- Research Site - Mobile
Arizona
- Research Site - Gilbert
- Research Site - Phoenix
- Research Site - Sun City West
Connecticut
- Research Site - Hamden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,046 participants |
| Start Date | 2025-05-28 |
| Est. Completion | 2027-01-11 |
| Phase | Phase 3 |
What the registry record for NCT07000123 still lists
NCT07000123 is an interventional study that assigns participants to a tested intervention. Its 3,046 participants enrollment target places it among the larger protocols in the corpus, above the 2,675-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (14% higher).
The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07000123 names 20 study sites across 5 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT07000123 about?
NCT07000123 is a clinical study titled "A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event". This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the partici...
What is the current status of trial NCT07000123?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 3,046 participants. The study started on 2025-05-28. Estimated completion is 2027-01-11.
What conditions does trial NCT07000123 study?
This clinical trial studies the following conditions: Cardiovascular Disease.
What interventions are being tested in trial NCT07000123?
The interventions under investigation include: Placebo (DRUG), AZD0780 (DRUG).
Who is sponsoring clinical trial NCT07000123?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07000123 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07000123's enrollment target sits among peer trials
3,046 23rd of 137 higher than 115 of 137 other Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RECRUITING · Phase 3
-
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
RECRUITING · Phase 3
-
VITAL Rhythm Study
ACTIVE NOT RECRUITING · Phase 3
-
Vitamin D and Omega-3 Trial (VITAL)
ACTIVE NOT RECRUITING · Phase 3
-
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
ACTIVE NOT RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07116967 · 3,040 participants · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- NCT06667700 · 3,082 participants · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI